Matching articles for "Beovu"

A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • May 2, 2022;  (Issue 1649)
The FDA has approved Susvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet)...
The FDA has approved Susvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet) age-related macular degeneration (nAMD) in patients who have previously responded to at least two intravitreal injections of a VEGF inhibitor. Ranibizumab intravitreal injection (Lucentis) has been available since 2006 for monthly treatment of nAMD. The FDA has approved ranibizumab-nuna (Byooviz), a biosimilar of Lucentis and the first ophthalmologic biosimilar; it will be available in June 2022.
Med Lett Drugs Ther. 2022 May 2;64(1649):71-2 | Show Full IntroductionHide Full Introduction

Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema

   
The Medical Letter on Drugs and Therapeutics • March 21, 2022;  (Issue 1646)
Faricimab-svoa (Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of...
Faricimab-svoa (Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It is the first drug to become available in the US that targets two pathways involved in maintaining vascular homeostasis. Several VEGF inhibitors are available for treatment of nAMD and DME (see Table 2).
Med Lett Drugs Ther. 2022 Mar 21;64(1646):45-6 | Show Full IntroductionHide Full Introduction

Addendum: Brolucizumab (Beovu) for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • March 9, 2020;  (Issue 1593)
We reviewed brolucizumab (Beovu – Novartis) for treatment of neovascular (wet) age-related macular degeneration in our February 10 issue. On February 23, the American Society of Retina Specialists reported...
We reviewed brolucizumab (Beovu – Novartis) for treatment of neovascular (wet) age-related macular degeneration in our February 10 issue. On February 23, the American Society of Retina Specialists reported that 14 patients who received the drug have developed retinal vasculitis, a potentially vision-threatening complication.
Med Lett Drugs Ther. 2020 Mar 9;62(1593):40 | Show Full IntroductionHide Full Introduction

Brolucizumab (Beovu) for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • February 10, 2020;  (Issue 1591)
Brolucizumab-dbll (Beovu — Novartis), a vascular endothelial growth factor (VEGF) inhibitor, has been approved by the FDA as an intravitreal injection for treatment of neovascular (wet) age-related...
Brolucizumab-dbll (Beovu — Novartis), a vascular endothelial growth factor (VEGF) inhibitor, has been approved by the FDA as an intravitreal injection for treatment of neovascular (wet) age-related macular degeneration (AMD). It is the fourth VEGF inhibitor to be approved in the US for this indication; bevacizumab (Avastin, and others), a VEGF inhibitor FDA-approved for treatment of breast cancer and other malignancies, has been used off-label for this indication for years.
Med Lett Drugs Ther. 2020 Feb 10;62(1591):23-4 | Show Full IntroductionHide Full Introduction

Drugs for Common Eye Disorders

   
The Medical Letter on Drugs and Therapeutics • December 2, 2019;  (Issue 1586)
This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate...
This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.
Med Lett Drugs Ther. 2019 Dec 2;61(1586):187-94 | Show Full IntroductionHide Full Introduction